Metabotropic glutamate receptor 5 modulators and their potential therapeutic applications

Bibliography

• JACOBY E, BOUHELAL R, GERSPACHER M, SEUWEN K: The 7TM G-protein-coupled receptor target family. Chem. Med. Chem. (2006) 1:760-782.
   Google Scholar
• O'BRIEN JA, LEMAIRE W, CHEN T-B et al.: A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol. Pharmacol. (2003) 64(3):731-740.
   PubMed Web of Science ®Google Scholar
• CHRISTOPOULOS A, KENAKIN T: G-protein-coupled receptor allosterism and complexing. Pharmacol. Rev. (2002) 54(2):323-374.
   PubMed Web of Science ®Google Scholar
• MAY LT, CHRISTOPOULOS A: Allosteric modulators of G-protein-coupled receptors. Curr. Opin. Pharmacol. (2003) 3(5):551-556.
   PubMed Web of Science ®Google Scholar
• JOHNSON MP, NISENBAUM ES, LARGE TH et al.: Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Biochem. Soc. Trans. (2004) 32:881-887.
   PubMedGoogle Scholar
• PIN J-P, GALVEZ T, PREZEAU L: Evolution, structure, and activation mechanism of family 3/C G-protein- coupled receptors. Pharmacol. Therapeut. (2003) 98(3):325-354.
   PubMed Web of Science ®Google Scholar
• PARMENTIER M-L, PREZEAU L, BOCKAERT J, PIN J-P: A model for the functioning of family 3 GPCRs. Trends Pharmacol. Sci. (2002) 23(6):268-274.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ TW, FRIMURER TM, HOLST B, ROSENKILDE MM, ELLING CE: Molecular mechanism of 7TM receptor activation – a global toggle switch model. Ann. Rev. Pharmacol. Toxicol. (2006) 46(1):481-519.
   PubMed Web of Science ®Google Scholar
• PIN JP, ACHER F: The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr. Drug Targets CNS Neurol. Disord. (2002) 1:297-317.
   PubMed Web of Science ®Google Scholar
• SCHOEPP DD, JANE DE, MONN JA: Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology (1999) 38:1431-1476.
   PubMed Web of Science ®Google Scholar
• VARNEY MA, COSFORD ND, JACHEC C et al.: SIB-1757 and SIB-1893: selective, non-competitive antagonists of metabotropic glutamate receptor type 5. J. Pharmacol. Exp. Ther. (1999) 290(1):170-181.
   PubMed Web of Science ®Google Scholar
• GASPARINI F, LINGENHOHL K, STOEHR N et al.: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology (1999) 38(10):1493-1503.
   PubMed Web of Science ®Google Scholar
• MATHIESEN JM, SVENDSEN N, BRÄUNER-OSBORNE H, THOMSEN C, RAMIREZ MT: Positive allosteric modulation of the human metabotropic glutamate receptor 4(hmGluR4) by SIB-1893 and MPEP. Br. J. Pharmacol. (2003) 138(6):1026-1030.
   PubMed Web of Science ®Google Scholar
• MOVSESYAN VA, O'LEARY DM, FAN L et al.: mGluR5 antagonists 2-methyl- 6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. (2001) 296(1):41-47.
   PubMed Web of Science ®Google Scholar
• COSFORD ND, TEHRANI L, ROPPE J et al.: 3-[(2-Methyl-1,3-thiazol-4-yl)- ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. (2003) 46(2):204-206.
   PubMed Web of Science ®Google Scholar
• COSFORD ND, ROPPE J, TEHRANI L et al.: [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5(mGlu5) receptor. Bioorg. Med. Chem. Lett. (2003) 13(3):351-354.
   PubMed Web of Science ®Google Scholar
• SABBATINI FM, MICHELI F: Metabotropic glutamate receptors: potential therapeutic applications of recently disclosed new chemical entities. Expert Opin. Ther. Pat. (2004) 14(11):1593-1604.
   Web of Science ®Google Scholar
• KEW JN: Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol. Therapeut. (2004) 104(3):233-244.
   PubMed Web of Science ®Google Scholar
• NISWENDER C, JONES CK, CONN P: New therapeutic frontiers for metabotropic glutamate receptors. Curr. Top. Med. Chem. (2005) 5(9):847-857.
   PubMedGoogle Scholar
• RITZÉN A, MATHIESEN JM, THOMSEN C: Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin. Pharmacol. Toxicol. (2005) 97(4):202-213.
   PubMed Web of Science ®Google Scholar
• SLASSI A, ISAAC M, EDWARDS L et al.: Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. Curr. Top. Med. Chem. (2005) 5(9):897-911.
   PubMed Web of Science ®Google Scholar
• WILLIAMS DL, Jr., LINDSLEY C: Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). Curr. Top. Med. Chem. (2005) 5(9):825-846.
   PubMed Web of Science ®Google Scholar
• FUNDYTUS ME: Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs (2001) 15(1):29-58.
   PubMed Web of Science ®Google Scholar
• JAVITT DC: Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatr. (2004) 9:984-997.
   PubMed Web of Science ®Google Scholar
• SWANSON CJ, BURES M, JOHNSON MP et al.: Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. (2005) 4(2):131-144.
   PubMed Web of Science ®Google Scholar
• CHAVEZ-NORIEGA LE, SCHAFFHAUSER H, CAMPBELL UC: Metabotropic glutamate rceptors: potential drug targets for the treatment of schizophrenia. Curr. Drug Targets CNS Neurol. Disord. (2002) 1(3):261-281.
   PubMedGoogle Scholar
• PALUCHA A, PILC A: The involvement of glutamate in the pathophysiology of depression. Drug News Perspect. (2005) 18(4):262-268.
   PubMed Web of Science ®Google Scholar
• LI X, NEED AB, BAEZ M, WITKIN JM: Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J. Pharmacol. Exp. Ther. (2006) 319(1):254-259.
   PubMed Web of Science ®Google Scholar
• URE J, BAUDRY M, PERASSOLO M: Metabotropic glutamate receptors and epilepsy. J. Neurol. Sci. (2006) 247(1):1-9.
   PubMed Web of Science ®Google Scholar
• SIMONYI A, SCHACHTMAN TR, CHRISTOFFERSEN GR: The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect. (2005) 18(6):353-361.
   PubMedGoogle Scholar
• BALSCHUN D, ZUSCHRATTER W, WETZEL W: Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience (2006) 142(3):691-702.
   PubMed Web of Science ®Google Scholar
• MARINO MJ, VALENTI O, CONN PJ: Glutamate receptors and Parkinson's disease: opportunities for intervention. Drug. Aging (2003) 20(5):377-397.
   PubMed Web of Science ®Google Scholar
• PHILLIPS JM, LAM HA, ACKERSON LC, MAIDMENT NT: Blockade of mGluR5 glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur. J. Neurosci. (2006) 23(1):151-160.
   PubMedGoogle Scholar
• ARMENTERO M-T, FANCELLU R, NAPPI G, BRAMANTI P, BLANDINI F: Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol. Dis. (2006) 22(1):1-9.
   PubMed Web of Science ®Google Scholar
• FRISBY CL, MATTSSON JP, JENSEN JM et al.: Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology (2005) 129:995-1004.
   PubMed Web of Science ®Google Scholar
• JENSEN J, LEHMANN A, UVEBRANDT A et al.: Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur. J. Pharmacol. (2005) 519:154-157.
   PubMed Web of Science ®Google Scholar
• BEAR MF, HUBER KM, WARREN ST: The mGluR theory of fragile X mental retardation. Trends Neurosci. (2004) 27(7):370-377.
   PubMed Web of Science ®Google Scholar
• HAGERMAN RJ, ONO MY, HAGERMAN PJ: Recent advances in fragile X: a model for autism and neurodegeneration. Curr. Opin. Psychiatr. (2005) 18(5):490-496.
   PubMed Web of Science ®Google Scholar
• HAMILL TG, KRAUSE S, RYAN C et al.: Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse (2005) 56(4):205-216.
   PubMedGoogle Scholar
• AMETAMEY SM, KESSLER LJ, HONER M et al.: Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J. Nucl. Med. (2006) 47(4):698-705.
   PubMed Web of Science ®Google Scholar
• SEVERANCE AJ, PARSEY RV, KUMAR JSD et al.: In vitro and in vivo evaluation of [11C]MPEPy as a potential PET ligand for mGlu5 receptors. Nuc. Med. Biol. (2006) 33(8):1021-1027.
   Google Scholar
• HINTERMANN S, VRANESIC I, ALLGEIER H et al.: ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. Bioorg. Med. Chem. (2007) 15(2):903-914.
   PubMed Web of Science ®Google Scholar
• SHAO B, HUANG J, SUN Q et al.: 4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists. Bioorg. Med. Chem. Lett. (2005) 15(3):719-723.
   PubMedGoogle Scholar
• DUBUISSON D, DENNIS SG: The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain (1977) 4:161-174.
   PubMed Web of Science ®Google Scholar
• BRADBURY MJ, CAMPBELL U, GIRACELLO D et al.: Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. J. Pharmacol. Exp. Ther. (2005) 313(1):395-402.
   PubMedGoogle Scholar
• ROPPE J, SMITH ND, HUANG D et al.: Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J. Med. Chem. (2004) 47(19):4645-4648.
   PubMed Web of Science ®Google Scholar
• COSFORD ND, ROPPE J, TEHRANI L et al.: [3H]-Methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5(mGlu5) receptor. Bioorg. Med. Chem. Lett. (2003) 13(3):351-354.
   PubMed Web of Science ®Google Scholar
• SCHULZ B, FENDT M, GASPARINI F et al.: The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)- pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology (2001) 41(1):1-7.
   PubMedGoogle Scholar
• BUSSE CS, BRODKIN J, TATTERSALL D et al.: The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3- thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology (2004) 29:1971-1979.
   PubMed Web of Science ®Google Scholar
• POON SF, EASTMAN BW, CHAPMAN DF et al.: 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5(mGlu5) receptor antagonist. Bioorg. Med. Chem. Lett. (2004) 14(22):5477-5480.
   PubMedGoogle Scholar
• HUANG D, POON SF, CHAPMAN DF et al.: 2- 2-[3-(Pyridin-3-yloxy)phenyl]- 2H-tetrazol-5-yl pyridine: a highly potent, orally active, metabotropic glutamate subtype 5(mGlu5) receptor antagonist. Bioorg. Med. Chem. Lett. (2004) 14(22):5473-5476.
   PubMedGoogle Scholar
• EASTMAN B, CHEN C, SMITH ND et al.: Expedited SAR study of an mGluR5 antagonists: generation of a focused library using a solution-phase Suzuki coupling methodology. Bioorg. Med. Chem. Lett. (2004) 14(22):5485-5488.
   PubMedGoogle Scholar
• GREEN MD, JIANG X, KING CD: Inhibition of human hepatic CYP isoforms by mGluR5 antagonists. Life Sci. (2004) 75(8):947-953.
   PubMedGoogle Scholar
• SMITH ND, POON SF, HUANG D et al.: Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5(mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity. Bioorg. Med. Chem. Lett. (2004) 14(22):5481-5484.
   PubMedGoogle Scholar
• WILLIAMS DL, Jr., LINDSLEY C: Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). Curr. Top. Med. Chem. (2005) 5(9):825-846.
   PubMed Web of Science ®Google Scholar
• LINDSLEY CW, WISNOSKI DD, LEISTER WH et al.: Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)- benzamides that potentiate receptor function in vivo. J. Med. Chem. (2004) 47(24):5825-5828.
   PubMed Web of Science ®Google Scholar
• DE PAULIS T, HEMSTAPAT K, CHEN Y et al.: Substituent effects of N-(1,3-di- phenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J. Med. Chem. (2006) 49(11):3332-3344.
   PubMedGoogle Scholar
• KINNEY GG, O'BRIEN JA, LEMAIRE W et al.: A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. (2005) 313(1):199-206.
   PubMed Web of Science ®Google Scholar
• GEYER MA, KREBS-THOMSON K, BRAFF DL, SWERDLOW NR: Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (2001) 156:117-154.
   PubMed Web of Science ®Google Scholar
• KAMENECKA TM, BONNEFOUS C, GOVEK S et al.: Dipyridyl amines: potent metabotropic glutamate subtype 5 receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15(19):4350-4353.
   PubMedGoogle Scholar
• BONNEFOUS C, VERNIER J-M, HUTCHINSON JH et al.: Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15(4):1197-1200.
   PubMedGoogle Scholar
• HAMMERLAND LG, JOHANSSON M, MALMSTROM J et al.: Structure–activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg. Med. Chem. Lett. (2006) 16(9):2467-2469.
   PubMedGoogle Scholar
• BACH P, NILSSON K, WÅLLBERG A et al.: A new series of pyridinyl-alkynes as antagonists of the metabotropic glutamate receptor 5 (mGluR5). Bioorg. Med. Chem. Lett. (2006) 16:4792-4795.
   PubMedGoogle Scholar
• BACH P, NILSSON K, SVENSSON T et al.: Structure–activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGluR5). Bioorg. Med. Chem. Lett. (2006) 16:4788-4791.
   PubMedGoogle Scholar
• LECCI A, BORSINI F, VOLTERRA G, MELI A: Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology (1990) 101(2):255-261.
   PubMedGoogle Scholar
• ARNT J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of amphetamine. Eur. J. Pharmacol. (1995) 283(1-3):62.
   Google Scholar
• KINNEY GG, BURNO M, CAMPBELL UC et al.: Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. (2003) 306(1):116-123.
   PubMed Web of Science ®Google Scholar
• MILLAN MJ, GIRARDON S, MULLOT J, BROCCO M, DEKEYNE A: Stereospecific blockade of marble-burying behaviour in mice by selective non-peptidergic neurokinin1 (NK1) receptor antagonists. Neuropharmacology (2002) 42:677-684.
   PubMedGoogle Scholar
• SPOOREN WP, VASSOUT A, NEIJT HC et al.: Anxiolytic-like effect of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6- (phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. (2000) 295(3):1267-1275.
   PubMed Web of Science ®Google Scholar
• VOGEL JR, BEER B, CLODY DE: A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia (1971) 21(1):1-7.
   PubMed Web of Science ®Google Scholar
• Reported at the 45th Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, Florida, 3 – 7 Dec (2006).
   Google Scholar
• PORTER RH, JAESCHKE G, SPOOREN W et al.: Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. (2005) 315(2):711-721.
   PubMed Web of Science ®Google Scholar
• ITIL TM, SEAMAN BA, HUQUE M et al.: The clinical and quantitative EEG effects and plasma levels of fenobam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. Curr. Ther. Res. (1978) 24:708-724.
   Google Scholar
• WU WN, MCKOWN LA, O'NEILL PJ: In vitro and in vivo metabolism of the antianxiolytic agent fenobam in the rat. J. Pharmaceutical Sciences (1995) 84(2):185-189
   PubMedGoogle Scholar
• WÅLLBERG A, NILSSON K, ÖSTERLUND K et al.: Phenyl ureas of creatinine as mGluR5 antagonists. A structure–activity relationship study of fenobam analogues. Bioorg. Med. Chem. Lett. (2006) 16(5):1142-1145.
   PubMedGoogle Scholar
• JAESCHKE G, PORTER R, BUTTELMANN B et al.: Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists. Bioorg. Med. Chem. Lett. (2007) 17(5):1307-1311.
   PubMedGoogle Scholar